Loading patent…
AssigneeMolecular Geriatrics Corporation
InventorsJohn Francis DeBernardis, Daniel Joseph Kerkman, Raymond Paul Zinkowski
Estimating the term…
Disclosed are compounds of formula I: or the pharmaceutically acceptable salts thereof wherein X is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl; Z is nitrogen or CH; Ar1 and Ar2 independently represent aryl groups; and Y is hydrogen; or Y and R1 or R2 together represent CH2; CH2CH2; CH20; CH2S forming a five or six membered ring and such ring may be optionally substituted with loweralkyl or phenyl; or pharmaceutically acceptable salts thereof, useful in the treatment of neoplastic diseases, and bacterial or fungal infections, and for preventing or decreaseing the production of abnormally phosphorylated paired helical filament (PHF) epitopes associated with Alzheimer's Disease and, therefore for treating Alzheimer's Disease.
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
A method of inhibiting the formation of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease comprising administering to a patient in need thereof an amount of a compound effective to inhibit the formation of the abnormally phosphorylated epitopes, where the compound is:
Dependencies are inferred from the claim text.